Faes Farma, S.A.
19
0
0
17
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
5.3%
1 terminated/withdrawn out of 19 trials
94.4%
+7.9% vs industry average
42%
8 trials in Phase 3/4
12%
2 of 17 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (19)
Efficacy and Safety of Hemorrane Plus Versus Hemorrane and Versus Placebo in Patients With Uncomplicated Haemorrhoids
Role: lead
Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis.
Role: lead
Efficacy and Safety of Calcifediol vs Placebo in Subjects With Vitamin D Deficiency
Role: lead
A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
Role: lead
Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children
Role: lead
A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.
Role: lead
Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
Role: collaborator
Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR
Role: lead
PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)
Role: lead
Human Mass Balance Study With Bilastine
Role: lead
Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU)
Role: lead
Oral Bioavailability of Bilastine
Role: lead
Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension
Role: lead
Bilastine Updosing - Characterization of Underlying Mechanisms
Role: collaborator
A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber
Role: lead
A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine
Role: lead
A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine
Role: lead
Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis
Role: lead
Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria
Role: lead
All 19 trials loaded